Oral medication and fatigue in multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how the oral medication teriflunomide (Aubagio) affects tiredness and daily activities in people with relapsing forms of multiple sclerosis. If you are starting this treatment as part of your regular care, the study will track your experience over a year to see how it impacts your energy and function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have relapsing MS (either relapsing-remitting or active secondary progressive).
- You are just starting a medication called teriflunomide (Aubagio).
- You can walk (with or without help) and can complete study tasks.
- You are not pregnant or breastfeeding.
- You can commit to study visits at the start, 3, 6, and 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether solriamfetol, a medication that promotes wakefulness, can reduce fatigue in people with multiple sclerosis. If you struggle with tiredness and sleepiness, this trial may help you understand how this drug works for MS-related fatigue.
This study looks at how multiple sclerosis (MS) affects your thinking, sleep, and tiredness. It compares people with MS who have at least mild fatigue to people without MS who also have sleep problems, to understand these issues better.
This study will test different parts of cognitive behavioral therapy to see which ones help with fatigue in people with multiple sclerosis. You will participate in sessions that may involve changing thoughts about fatigue, scheduling activities, or addressing related emotions like depression or anxiety.
This trial tests an online self-management program to help reduce fatigue in people with MS. You'll use a website or app over 24 weeks, and researchers will check how well it works.
This trial studies whether giving immunoglobulins (antibody medicines) can improve fatigue in people with multiple sclerosis (MS). It will enroll only people whose MS and fatigue are stable and meet specific blood/health criteria.
This study tests two non-invasive brain stimulation treatments—TMS and tDCS—to see if they can reduce fatigue in people with relapsing-remitting MS. The goal is to find a safe, drug-free way to help you feel less tired.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.